REGEN
Get REGENGet Now
LibraryToolsNotesBlogFAQ

Best Peptides for Beginners

Where people usually start, reordered by how much evidence actually backs each one.

6 Min Read
RE
Compiled from published research · Continuously updated

How this is graded

Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.

1. Semaglutide

Sgrade0.25–2.4 mgHalf-life ~7 days

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that slows gastric emptying, increases satiety, and improves insulin sensitivity and glucose control. Originally developed for type 2 diabetes, it has become a leading weight-loss therapy. Dosing is titrated up slowly over weeks to minimize gastrointestinal side effects like nausea. It directly affects metabolic markers — expect improvements in HbA1c, fasting glucose, and body composition. Not typically stacked with growth or healing peptides; used as a standalone metabolic tool.

  • Weight Loss (grade S) — 3 cited studies through 2023
  • Immune Function (grade B) — post-hoc STEP proteomic and inflammation sub-analyses, not a primary-endpoint RCT
  • Body Composition (grade B) — DEXA sub-analyses of Phase 3 trials show fat-mass-dominant loss
  • Muscle Growth (grade D) — no muscle-growth benefit; DEXA sub-analyses show lean mass falls with total weight
  • Cognitive Function (grade D) — 1 cited study through 2024

Strongest study: EVOKE / EVOKE+, Alzheimers Dement (2026) — missed primary endpoint in early Alzheimer's · readout Mar 2026 · N=1840

Full Semaglutide reference

2. GHK-Cu

Cgrade1–2 mgHalf-life ~1 hour

GHK-Cu is a naturally occurring copper-binding tripeptide whose plasma levels decline with age. It is best known for stimulating collagen and elastin production, improving skin firmness and wound healing, and supporting hair follicle health. It also has antioxidant and anti-inflammatory properties and has been studied for gene-expression effects associated with tissue remodeling. Available both as an injectable for systemic effects and topically for skin and hair. Often part of longevity and aesthetics protocols rather than performance stacks.

  • Skin & Aesthetics (grade B) — large observational cosmetic literature; the two controlled trials missed objective endpoints
  • Longevity (grade D) — 2026 C. elegans lifespan study, animal-only
  • Joint & Tendon Health (grade D) — preclinical only (Fu 2015, rat ACL reconstruction)

Strongest study: Wen C. elegans lifespan, Biogerontology (2026) — mean lifespan extension via mitochondrial + DAF-16/SKN-1 regulation · C. elegans

Full GHK-Cu reference

3. BPC-157

Cgrade250–500 mcgHalf-life ~30 minutes

BPC-157 is a 15-amino-acid partial sequence of body protection compound found in gastric juice. It is widely used in recovery protocols for its reported effects on tendon, ligament, muscle, and gut-lining repair. Mechanistically it is associated with upregulation of growth factor receptors and promotion of angiogenesis (new blood vessel formation), which supports tissue healing. It is frequently stacked with TB-500 for synergistic recovery and is a cornerstone of the healing-focused peptide protocol. Human clinical data is limited; most evidence is preclinical.

  • Joint & Tendon Health (grade C) — rodent-model reviews plus a small human case series; no RCT
  • Gut Health (grade C) — review of animal GI models (Sikiric 2020); no human trial
  • Cognitive Function (grade C) — 1 cited study through 2013

Strongest study: interstitial cystitis open-label pilot, Altern Ther Health Med (2024) — open-label, uncontrolled, no placebo · intravesical 10 mg · 10/12 reported full symptom resolution (not an RCT) · N=12

Full BPC-157 reference

4. Ipamorelin

Cgrade200–300 mcgHalf-life ~2 hours

Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to trigger a clean pulse of growth hormone from the pituitary, without the cortisol, prolactin, or hunger spikes seen with older secretagogues like GHRP-6. Its selectivity makes it one of the most popular and well-tolerated GH peptides. It is typically paired with a GHRH like CJC-1295 to produce a larger, more physiological GH release. Common goals are recovery, sleep quality, and gradual improvements in body composition. Track IGF-1 to confirm response.

  • Body Composition (grade D) — flagship citation is animal pharmacology (Raun 1998); human data is PK-only
  • Muscle Growth (grade D) — no direct human muscle-outcome trial; extrapolated from GH/IGF-1 response
  • Sleep Quality (grade D) — 2 cited studies through 2003

Strongest study: ghrelin agonist meta, JCEM (2015) — consistent IGF-1 + body comp · review

Full Ipamorelin reference

5. TB-500

Dgrade2–5 mgHalf-life ~2-3 days

TB-500 is a synthetic version of the active region of Thymosin Beta-4, a naturally occurring protein involved in cell migration, blood vessel formation, and tissue repair. It works systemically rather than locally, making it popular for whole-body recovery, muscle and tendon healing, and reducing stiffness. It upregulates actin, a protein central to cell movement and wound healing. TB-500 is most commonly paired with BPC-157 in healing blocks, where the two are seen as complementary — BPC-157 acting more locally and TB-500 systemically. Most evidence is preclinical or anecdotal.

  • Joint & Tendon Health (grade D) — parent-molecule eye-drop trials only, and their phase 3s missed endpoints; no TB-500 human data

Strongest study: RegeneRx RGN-259 dry eye, Cornea (2019) — full-length Tβ4 eye drops, encouraging in early phase 2; later phase 3 trials (ARISE-3, SEER-1, SEER-3) missed · N=96

Full TB-500 reference

At a glance

CompoundGradeReported doseHalf-life
SemaglutideSgrade0.25–2.4 mg · 1x weekly (titrated)~7 days
GHK-CuCgrade1–2 mg · 1x daily (injectable)~1 hour
BPC-157Cgrade250–500 mcg · 1-2x daily~30 minutes
IpamorelinCgrade200–300 mcg · 1-3x daily~2 hours
TB-500Dgrade2–5 mg · 2x weekly (loading), then 1x weekly~2-3 days

Frequently asked questions

Which peptide has the most evidence for beginners?

Semaglutide, at research grade S. REGEN Research Tier S — official / regulatory approval (FDA or foreign equivalent).

How many compounds are compared here?

5: Semaglutide, GHK-Cu, BPC-157, Ipamorelin, TB-500.

What doses are reported for Semaglutide?

Published protocols report 0.25–2.4 mg, 1x weekly (titrated). This is what the literature describes, not a recommendation.

References

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity · Wilding JPH, et al. · 2021
  2. FDA Approval Announcement for Wegovy (2021). · 2021
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · Lincoff AM, Brown-Frandsen K, Colhoun HM et al. · 2023
  4. Semaglutide, a glucagon like peptide-1 receptor agonist with ... - NIH · Mahapatra MK, Karuppasamy M, Sahoo BM · 2022
  5. Semaglutide Mechanism of Action Review. PMC. · Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A · 2022
  6. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. · McGuire DK, Marx N, Mulvagh SL et al. · 2025
  7. Semaglutide | C187H291N45O59 | CID 56843331 - PubChem - NIH
  8. Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
  9. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. · McGuire DK, Busui RP, Deanfield J et al. · 2023
  10. Semaglutide - StatPearls - NCBI Bookshelf
  11. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021. · Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · 2021
  12. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. · Perkovic V, Tuttle KR, Rossing P et al. · 2024
  13. Molecular mechanisms of semaglutide and liraglutide as a ... · Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK · 2024
  14. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration · Pickart L, Margolina A · 2018
  15. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. · Yang ZX, He XT, Li X, Lian YS, Sun JY · 2018
  16. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. · Miller TR, Wagner JD, Baack BR et al. · 2006
  17. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. · Taylor TH, Chang CC, Elliott T, Colturato LF, Kort HI, Nagy ZP · 2008
  18. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. · Fu SC, Cheuk YC, Chiu WY et al. · 2015
  19. The potential of GHK as an anti-aging peptide - PMC - NIH · Dou Y, Lee A, Zhu L, Morton J, Ladiges W · 2020
  20. Canapp SO Jr, et al. The anti-inflammatory effect of the naturally occurring peptide GHK. Veterinary Surgery. 2003;32(4):391-396. · Russell IF · 2003
  21. Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. · Deng M, Zhang Q, Yan L et al. · 2023
  22. The human tri-peptide GHK and tissue remodeling · Pickart L · 2008
  23. Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins' activity for fascia regeneration. · Wang R, Xu Y, Saiding Q et al. · 2026
  24. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health - PMC · Pickart L, Vasquez-Soltero JM, Margolina A · 2012
  25. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Sikiric P, et al. · 2011
  26. Brain-gut axis and pentadecapeptide BPC 157 · Sikiric P, et al. · 2016
  27. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. · Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM · 2025
  28. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. · Lee E, Padgett B · 2021
  29. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM · 2025
  30. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. · Lee E, Walker C, Ayadi B · 2024
  31. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. · Chang CH, Tsai WC, Hsu YH, Pang JH · 2014
  32. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. · Lee E, Burgess K · 2025
  33. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats · Xue XC, Wu YJ, Gao MT, Li WG, Zhao N, Wang ZL, Bao CJ, Yan Z, Zhang YQ · 2004
  34. ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial.
  35. Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats. · Mirković I, Kralj T, Lozić M et al. · 2020
  36. The pharmacological properties of the novel peptide BPC 157 (PL-10) · Sikiric P · 1999
  37. Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. · Amic F, Drmic D, Bilic Z et al. · 2018
  38. Ipamorelin, the first selective growth hormone secretagogue · Raun K, et al. · 1998
  39. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
  40. Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
  41. Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561. · Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW · 1998
  42. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. · Gobburu JV, Agersø H, Jusko WJ et al. · 1999
  43. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. · Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H · 1999
  44. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. · Semenistaya E, Zvereva I, Thomas A et al. · 2015
  45. Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66. · Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM · 2001
  46. A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. · Timms M, Hall N, Levina V et al. · 2014
  47. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a ... · Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C · 2012
  48. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231. · Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E · 2007
  49. Thymosin beta4 and tissue regeneration · Goldstein AL, et al. · 2012
  50. Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015. · Martinez JO, Evangelopoulos M, Bhavane R, Acciardo S, Salvatore F, Liu X, Ferrari M, Tasciotti E · 2015
  51. Thymosin β4 Promotes Dermal Healing. · Kleinman HK, Sosne G · 2016
  52. Gene ResultTMSB4X thymosin beta 4 X-linked [ (human)] - NCBI
  53. Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2012. · Meyer M, Elmer S, Jäncke L · 2012
  54. Biological activities of thymosin beta4 defined by active sites in short ... · Sosne G, Qiu P, Goldstein AL, Wheater M · 2010
  55. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. · Pinto B, Pierotti R, Canale G, Reali D · 1999
  56. Identification of glutamine as a potential therapeutic target in dry eye disease. · Chen X, Zhang C, Peng F et al. · 2025
  57. Thymosin Beta-4 - an overview | ScienceDirect Topics
  58. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007. · Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T, Tuominen RK, Saarma M · 2007
  59. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. · Bock-Marquette I, Maar K, Maar S et al. · 2023
All guides and comparisons

Put the whole protocol
in one place.

Download nowGet Now